Celine Cottereaux
Romainville, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Pharmacological Characterization of GLPG3667, a Tyrosine Kinase 2-Selective Inhibitor, for the Treatment of Inflammatory and Autoimmune Diseases.
Journal: Inflammation
Published: December 24, 2025
Design of a potent and selective dual JAK1/TYK2 inhibitor.
Journal: Bioorganic & medicinal chemistry
Published: May 07, 2024
IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases.
Journal: Science translational medicine
Published: February 15, 2023
Pharmacological characterization of GLPG1972/S201086, a potent and selective small-molecule inhibitor of ADAMTS5.
Journal: Osteoarthritis and cartilage
Published: March 15, 2021
Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis.
Journal: Journal of medicinal chemistry
Published: March 15, 2021
Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial.
Journal: Journal of medicinal chemistry
Published: September 09, 2020
Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis.
Journal: Journal of medicinal chemistry
Published: April 18, 2017
Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization.
Journal: BMC musculoskeletal disorders
Published: February 26, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026